Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence
CL Yu, CH Yang, CC Chi - BioDrugs, 2020 - Springer
Background The last decade has witnessed the increasing use of biologics for the treatment
of ankylosing spondylitis (AS). Drug survival is an outcome incorporating real-world …
of ankylosing spondylitis (AS). Drug survival is an outcome incorporating real-world …
Application of machine learning in the diagnosis of axial spondyloarthritis
Application of machine learning in the diagnosis of axial sp... : Current Opinion in
Rheumatology Application of machine learning in the diagnosis of axial spondyloarthritis …
Rheumatology Application of machine learning in the diagnosis of axial spondyloarthritis …
[HTML][HTML] Insight into the quality of life of patients with ankylosing spondylitis: real-world data from a US-based life impact survey
JT Rosenbaum, L Pisenti, Y Park… - Rheumatology and therapy, 2019 - Springer
Methods Demographic and QOL data were collected from a random sample of patients
associated with the Spondylitis Association of America (SAA) from July to December 2017 …
associated with the Spondylitis Association of America (SAA) from July to December 2017 …
Healthcare utilization and direct costs in patients with ankylosing spondylitis using a large US administrative claims database
Introduction In addition to the considerable patient and societal burdens, the financial
burdens of ankylosing spondylitis (AS) are substantial. Understanding both all-cause and …
burdens of ankylosing spondylitis (AS) are substantial. Understanding both all-cause and …
Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross …
SH Lee, YG Kim, SG Lee, SH Lee… - International Journal …, 2022 - Wiley Online Library
Aim To provide in‐depth understanding of real‐world tumor necrosis factor inhibitor (TNFi)
treatment patterns in patients with ankylosing spondylitis (AS) and treatment satisfaction …
treatment patterns in patients with ankylosing spondylitis (AS) and treatment satisfaction …
Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis
BACKGROUND: Interventions for ankylosing spondylitis (AS) have improved patient-
reported outcomes (PROs) in clinical studies. However, limited data exist associating these …
reported outcomes (PROs) in clinical studies. However, limited data exist associating these …
Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study
FA Acurcio, AA Guerra Junior… - Current Medical …, 2020 - Taylor & Francis
Objective To evaluate persistence on conventional DMARDs (cDMARDs) and anti-TNF
therapies, and to identify potential determinants of discontinuation among individuals with …
therapies, and to identify potential determinants of discontinuation among individuals with …
Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: a descriptive cohort study …
S Chen, T Fukasawa, A Ikeda, M Takeuchi… - Heliyon, 2023 - cell.com
Objective We evaluated adherence to and 1-year persistence of two third-generation anti-
seizure medications (ASMs), lacosamide and perampanel, in adult patients with focal …
seizure medications (ASMs), lacosamide and perampanel, in adult patients with focal …
Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States
T Hunter, K Schroeder, D Sandoval… - Rheumatology and …, 2019 - Springer
Introduction The primary goals of treating ankylosing spondylitis (AS) patients are to
maximize long-term health-related quality of life through control of symptoms and …
maximize long-term health-related quality of life through control of symptoms and …
Sex differences in time to initiate NSAIDs or bDMARDs among patients with axial spondyloarthritis
Objective We evaluated sex differences in time to initiation of nonsteroidal anti‐inflammatory
agents (NSAIDs) or biologic disease modifying antirheumatic drugs (bDMARDs) among …
agents (NSAIDs) or biologic disease modifying antirheumatic drugs (bDMARDs) among …